1. Wu Y., Chen C., Chan Y. 2020. The outbreak of COVID-19: An overview. *J Chin Med. Assoc*. 83: 217–220.
2. World Health Organization. Coronavirus disease (COVID-19). https://www.who.int/health-topics/coronavirus (20.09.2021).
3. Bostancıklıoğlu M. 2020. Temporal Correlation Between Neurological and Gastrointestinal Symptoms of SARS-CoV-2. *Inflamm Bowel Dis*. 26: e89-e91.
4. COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. https://arcg.is/0fHmTX (20.09.2021).
5. Hale T. i wsp. 2021. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). *Nat. Hum. Behav*. 5: 529-538.
6. Flaxman S. i wsp. 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 584, 257-261.
7. Our World in Data. Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations?country=OWID\_WRL (20.09.2021).
8. Institute for Health Metrics and Evaluation. COVID-19 Projections: Poland. https://covid19.healthdata.org/poland (20.09.2021).
9. World Health Organization. COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (20.09.2021).
10. Al Kaabi N. i wsp. 2021. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA*. 326: 35-45.
11. Lundstrom K. 2021. Viral Vectors for COVID-19 Vaccine Development. *Viruses*. 13: 317.
12. Zollner A. i wsp. 2021. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. *EBioMedicine*. 70: 103539.
13. Bettini E., Locci M. 2021. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. *Vaccines (Basel)*. 9: 147.
14. Pardi N., Hogan M.J., Porter F.W., Weissman D. 2018. mRNA vaccines - a new era in vaccinology. *Nat. Rev. Drug Discov*. 17: 261-279.
15. Rodriguez-Coira J., Sokolowska M. 2021. SARS-CoV-2 candidate vaccines - composition, mechanisms of action and stages of clinical development. *Allergy*. 76: 1922-1924.
16. Tian J.H. i wsp. 2021. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. *Nat. Commun*. 12: 372.
17. Huang Y., Yang C., Xu X.F., Xu W., Liu S.W. 2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol. Sin*. 41: 1141-1149.
18. Polack F.P. i wsp. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med*. 383: 2603-2615.
19. Baden L. i wsp. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med*. 384: 403-416.
20. Logunov D. i wsp. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet*. 397: 671-681.
21. Thomas S. i wsp. 2021. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine, *medRxiv* 2021.07.28.21261159.
22. Mahase E. 2021. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant, *BMJ*. 372: n296.
23. Tanriover M. i wsp. 2021. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet*. 398: 213-222.
24. Polinski J. i wsp. 2021. Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine. *medRxiv* 2021.09.10.21263385.
25. Sadoff J. i wsp. 2021. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N. Engl. J. Med*. 384: 2187-2201.
26. Voysey M. i wsp. 2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet*. 397: 881-891.
27. Zhu X. i wsp. 2021. Risk factors for mortality in patients over 70  years old with COVID-19 in Wuhan at the early break: retrospective case series. *BMC Infect. Dis*. 21: 821.
28. Government of Canada. Reported side effects following COVID-19 vaccination in Canada. https://health-infobase.canada.ca/covid-19/vaccine-safety/summary.html (20.09.2021).
29. Norwegian Medicines Agency. Reported suspected adverse reactions to COVID-19 vaccines as of 14.09.2021. https://legemiddelverket.no/english/covid-19-and-medicines/vaccines-against-covid-19/reported-suspected-adverse-reactions-of-covid-19-vaccines#click-here-to-see-previous-weekly-reports (20.09.2021).
30. Wyller T.B., Kittang B.R., Ranhoff A.H., Harg P., Myrstad M. 2021. Nursing home deaths after COVID-19 vaccination. *Tidsskr Nor Legeforen*. 2021: 141.
31. Pottegard A. i wsp. 2021. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ*. 373: n1114.
32. Centers for Disease Control and Prevention, COVID-19 Breakthrough Case Investigations and Reporting, https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html (20.09.2021).
33. Klein N.P. i wsp. 2021. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. *JAMA*. https://jamanetwork.com/journals/jama/fullarticle/2784015 (20.09.2021).
34. Menni C. i wsp. 2021. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *Lancet Infect. Dis*. 21: 939-949.
35. Barda N. i wsp. 2021. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N. Eng.l J. Med*. 385: 1078-1090.
36. Food and Drug Administration. FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine. https://www.fda.gov/media/144245/download (20.09.2021).
37. Food and Drug Administration. FDA Briefing Document: Moderna COVID-19 Vaccine. https://www.fda.gov/media/144434/download (20.09.2021).
38. Food and Drug Administration. FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. https://www.fda.gov/media/146217/download (20.09.2021).
39. Medicines and Healthcare products Regulatory Agency, Summary of Product Characteristics for Vaxzevria. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca (20.09.2021).
40. Macintyre C.R., Veness B., Berger D., Hamad N., Bari N. 2021. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia. *Vaccine*. 39: 4784-4787.
41. Groch S. 2021. Some nations using China’s vaccines are battling outbreaks. So do they work? *The Sydney Morning Herald*. https://www.smh.com.au/world/asia/some-nations-relying-on-china-s-vaccines-are-battling-outbreaks-so-do-the-vaccines-work-20210706-p5878h.html (20.09.2021).
42. Han B. i wsp. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis*. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext (20.09.2021).
43. Hitchings M. i wsp. 2021. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study. *medRxiv*. 2021.04.07.21255081.
44. Saeed B.Q., Al-Shahrabi R., Alhaj S.S., Alkokhardi Z.M., Adrees A.O. 2021. Side effects and perceptions following Sinopharm COVID-19 vaccination. *Int. J. Infect. Dis*. 111: 219-226.
45. Tagoe E.T., Sheikh N., Morton A., Nonvignon J., Sarker A.R., Williams L., Megiddo I. 2021. COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions. *Front Public Health*. 9: 709127.
46. Khan H., Dabla-Norris E., Lima F., Sollaci A. 2021. Who Doesn’t Want to be Vaccinated? Determinants of Vaccine Hesitancy During COVID-19. International Monetary Fund. https://www.imf.org/en/Publications/WP/Issues/2021/05/06/Who-Doesnt-Want-to-be-Vaccinated-Determinants-of-Vaccine-Hesitancy-During-COVID-19-50244 (20.09.2021).
47. Phillips D.E., Dieleman J.L., Lim S.S., Shearer J. 2017. Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis. *BMC Health Serv. Res*. 17: 1-17.
48. Nelson K.N., Wallace A.S., Sodha S.V., Daniels D., Dietz V. 2016. Assessing strategies for increasing urban routine immunization coverage of childhood vaccines in low and middle-income countries: a systematic review of peer-reviewed literature. *Vaccine*. 34: 5495-5503.
49. Pieroni V., Facchini A., Riccaboni M. 2021. COVID-19 vaccination and unemployment risk: lessons from the Italian crisis, *Sci. Rep*. 11: 18538.
50. Bar-On Y.M. i wsp. 2021. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N. Engl. J. Med*. https://www.nejm.org/doi/full/10.1056/NEJMoa2114255 (20.09.2021).
51. Kołłątaj B., Kołłątaj W., Karwat I., Sobieszczański J., Panasiuk L. 2020. Anti-vaccine movements - health care, ignorance or a diversion aimed at destabilizing the health situation? Part 2. Contemporary conditions for the functioning and development of anti-vaccination movements, *Ann. Agric. Environ. Med*. 27: 553-561.